People with type 2 diabetes usually don't use insulin efficiently, and they may not make enough insulin to keep up with the body's demands. That's when people with type 2 diabetes often need to start taking insulin. (In people with type 1 diabetes, the immune system mistakenly attacks he...
Daily insulin injections can be burdensome to patients but are the cornerstone of type 1 diabetes management and often become necessary over time for type 2 diabetes. Could they soon become a thing of the past, asks Jacqui Wise The effectiveness of a new class of once weekly basal insulin, ...
As type 2 diabetes progresses, insulin therapy may help to optimize glycemic control.1,2 Basal insulin initiation is recommended when noninsulin glucose-lowering agents are insufficient for glycemic control.1,2 Insulin icodec is a once-weekly basal insulin that may improve treatment acceptance and ad...
Missedinsulin injectionsand inadequate dose titration of daily basal insulins can lead to suboptimal glycemic control in persons with type 2 diabetes. Once-weeklyinsulinicodec is a basal insulin analogue that is in development and is aimed at reducing treatment burden. A once-weekly dosing schedule ...
“If approved, we believe this innovation-which could be the world’s first once weekly insulin-could help people living with type 2 diabetes ready to start insulin treatment by reducing the number of injections needed.” Insulin icodec has been submitted for regulatory review in the Un...
“weekly injections can be burdensome for patients,” megret said. “a single shot a month could make it much easier for people living with diabetes or obesity to stick to their drug regimens, improving quality of life and reducing side effects and diabetes complications.” the...
Diabetes Ther. 2021;12(2):527–36. Article CAS Google Scholar Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021...
Eligible participants were adults aged at least 18 years without diabetes, with a body-mass index of at least 30 kg/m 2 or at least 27 kg/m 2 with hypertension or dyslipidaemia. Participants were randomly assigned (6:1) to subcutaneous self-injections of once-weekly cagrilintide (0·3, ...
growth hormone in the body. NGENLA is taken by injection just below the skin, administered via a device that allows for titration based on patient need. Compared to the growth hormone GENOTROPIN® (somatropin), its action in the body lasts longer, enabling...
However, its current formulation requires twice daily subcutaneous injections and does not provide continuous GLP-1R activation. Therefore, a long-acting release form of exenatide has been developed for use as a once-weekly injection, providing for convenient administration and continuous GLP-1R ...